Lung cancer (non-small-cell) - pemetrexed (maintenance): Review update - January 2013
Decision to defer the review
In January 2012 we wrote to stakeholders to inform them that the consideration of a review of TA181; Pemetrexed for the first line treatment of non small cell lung cancer was to be deferred and take place within 6 months of the publication of an independent Health Technology Assessment (HTA) report on ‘First-line therapy for adult patients with non-small-cell lung cancer’ that is currently being compiled by the Liverpool Review and Implementation Group (LRiG), Liverpool University. This paper is not expected to be published until June 2013 at the earliest.
There is considerable overlap between TA190 and TA181 and it is sensible to consider the review of these two pieces of guidance together. Consequently we have decided to defer the consideration of the review of TA190 to take place within 6 months of the publication of the HTA paper, when it will be considered for review along with TA181.
This page was last updated: 02 January 2013